Sequential designs for phase I clinical trials with late-onset toxicities

Area of Science:

• Clinical Trials Methodology
• Biostatistics
• Pharmacometrics

Background:

• Traditional phase I clinical trial designs necessitate complete follow-up of each patient cohort before initiating the next.
• This sequential approach can lead to impractically long trial durations, particularly for evaluating late-onset toxicities or chemopreventive agents.

Purpose of the Study:

• To introduce and evaluate the time-to-event continual reassessment method (TITE-CRM) for phase I clinical trials.
• To demonstrate TITE-CRM's ability to allow staggered patient entry and reduce overall trial duration.

Main Methods:

• The TITE-CRM is an extension of the continual reassessment method (CRM), incorporating a time-to-event framework.
• The method allows for staggered patient enrollment, unlike traditional designs.
• Theoretical convergence properties were proven, and simulation studies were conducted for performance evaluation.

Main Results:

• Simulation studies indicate TITE-CRM achieves accuracy and safety comparable to the traditional CRM.
• TITE-CRM significantly reduces trial duration; a 12-year trial could be completed in 2-4 years.
• The time-to-toxicity approach is applicable to other short-term toxicity study designs.

Conclusions:

• TITE-CRM offers a more efficient alternative for phase I clinical trials, especially those involving late-onset toxicities.
• The method accelerates the drug development process by shortening trial timelines without compromising safety or accuracy.
• TITE-CRM represents a significant advancement in adaptive clinical trial design.